Harvard Bioscience
(HBIO)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2018 | 12-2017 | 09-2017 | 06-2017 | 03-2017 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -4,064 | -865 | -1,864 | -1,447 | -1,066 |
| Depreciation Amortization | 1,927 | 3,845 | 2,901 | 1,911 | 933 |
| Income taxes - deferred | -1,354 | -1,584 | 0 | N/A | 0 |
| Accounts receivable | 149 | 196 | 1,000 | 125 | 410 |
| Accounts payable and accrued liabilities | 1,346 | -918 | -786 | -703 | -320 |
| Other Working Capital | 4,149 | -3,811 | -1,646 | -2,286 | -1,325 |
| Other Operating Activity | -1,705 | 4,194 | 2,391 | 2,265 | 758 |
| Operating Cash Flow | $448 | $1,057 | $1,996 | $-135 | $-610 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -493 | -878 | -677 | -437 | -198 |
| Net Acquisitions | -51,683 | N/A | N/A | N/A | N/A |
| Other Investing Activity | -13 | -39 | -39 | -39 | -30 |
| Investing Cash Flow | $-52,189 | $-917 | $-716 | $-476 | $-228 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 67,000 | 2,750 | 2,250 | 2,000 | 1,000 |
| Debt Repayment | -14,047 | -4,702 | -3,502 | -2,552 | -1,113 |
| Common Stock Issued | 219 | 160 | -101 | -77 | -155 |
| Other Financing Activity | -1,928 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | $51,244 | $-1,792 | $-1,353 | $-629 | $-268 |
| Exchange Rate Effect | 755 | 1,789 | 313 | 368 | 109 |
| Beginning Cash Position | 5,733 | 5,596 | 5,596 | 5,596 | 5,596 |
| End Cash Position | 5,991 | 5,733 | 5,836 | 4,724 | 4,599 |
| Net Cash Flow | $258 | $137 | $240 | $-872 | $-997 |
| Free Cash Flow | |||||
| Operating Cash Flow | 448 | 1,057 | 1,996 | -135 | -610 |
| Capital Expenditure | -493 | -890 | -677 | -437 | -198 |
| Free Cash Flow | -45 | 167 | 1,319 | -572 | -808 |